Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Moving Beyond Chemotherapy in Metastatic Pancreatic Cancer

April 22nd 2021

Zev A. Wainberg, MD, discusses the role of neoadjuvant chemotherapy in resectable pancreatic cancer, emerging approaches in locally advanced disease, the promise of PARP inhibitors in the metastatic setting, and other future research directions of interest.

Glofitamab Demonstrates Durable Responses in Relapsed/Refractory B-Cell Lymphoma

April 21st 2021

The novel T-cell–engaging bispecific antibody glofitamab demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive B-cell lymphoma.

Entering an Era of Immunotherapy-Based Combinations for Metastatic RCC

April 18th 2021

The frontline treatment landscape of renal cell carcinoma is exploding with immunotherapy-based options.

Role of PORT Diminishes in Early-Stage NSCLC, as Novel Approaches Emerge for Unresectable Stage III Disease

April 17th 2021

Kristen Marrone, MD, discusses the evolving role of postoperative radiotherapy in early-stage non–small cell lung cancer and ongoing trials examining the use of immunotherapy and targeted agents in patients with unresectable stage III disease.

Hutson Highlights Treatment Journey in Clear Cell RCC Case

April 16th 2021

When considering which frontline option to administer to a patient with renal cell carcinoma, it is important to first understand which risk group they belong to.

31-Gene Expression Profile Test Improves Risk Assessment in Cutaneous Melanoma

April 15th 2021

Combining the 31-gene expression profile test with current American Joint Committee on Cancer staging guidelines may improve risk assessment in patients with cutaneous melanoma, as well as determine which patients could be candidates for more intense follow-up.

Chronic irAEs After Adjuvant Anti–PD-1 Therapy More Common Than Previously Recognized in High-Risk Resected Melanoma

April 15th 2021

Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.

Novel Agents Move the Needle Forward in Metastatic Pancreatic Cancer

April 15th 2021

Raymond Wadlow, MD, discusses the emergence of combination chemotherapy regimens in metastatic pancreatic cancer and the promise of emerging strategies that are under exploration.

Triplet Combos Targeting ER, CDK4/6, and PIK3CA Inhibit Tumor Growth in ER+ Breast Cancer

April 14th 2021

A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.

Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC

April 13th 2021

Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.

Twice-Daily Poziotinib Improves Efficacy, Tolerability in EGFR- or HER2 Exon 20–Positive NSCLC

April 12th 2021

Administering the investigational TKI poziotinib at a twice-daily dose compared with once-daily dosing showed a reduction in both grade 3 or higher treatment emergent adverse effects and dose interruptions, as well as improved efficacy in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Trastuzumab Deruxtecan Shows Sensitivity in Various Levels of HER2-Expressing Gastric Cancer Cells

April 10th 2021

Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.

Saif Shares Key Treatment Considerations for Advanced Pancreatic Cancer

April 9th 2021

Wasif Saif, MD, discusses factors to consider when choosing a frontline treatment strategy in pancreatic cancer, highlights the hunt for helpful biomarkers of response to available options, and offers sequencing suggestions.

Research Efforts in HER2+ Breast Cancer Pick Up Speed Despite COVID-19

April 9th 2021

Jane L. Meisel, MD, discusses sequencing questions, tucatinib combinations under exploration, and emerging strategies for use in the treatment of patients with HER2-positive breast cancer.

Novel Agents Expand MDS Treatment Armamentarium After Years of Inactivity

April 8th 2021

Amit K. Verma, MD, spotlights new agents that have entered the myelodysplastic syndrome treatment arsenal and novel combinations currently under exploration, as well as efforts that are showing promise in patients with acute myeloid leukemia.

Bhave Spotlights Breakthroughs Made With Immunotherapy Combinations in TNBC

April 6th 2021

Chemoimmunotherapy has become the standard of care for the frontline treatment of patients with PD-L1–positive, locally advanced or metastatic triple-negative breast cancer. However, understanding which patients will derive the most benefit from the approach is in need of further exploration

Updated Data Confirm Clinical Benefit of Novel Immunotherapy Combos in HCC

April 6th 2021

Daniel Lin, MD, MS, highlights pivotal trials evaluating immunotherapy regimens in patients with hepatocellular carcinoma, remaining sequencing questions, and emerging regimens that are showing promise.

Lurbinectedin Makes a Splash in Second-Line SCLC

April 5th 2021

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Longer Follow-Up Is Imperative With Adjuvant CDK4/6 Inhibitors in ER+ Breast Cancer

April 5th 2021

Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor–positive breast cancer.

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

April 3rd 2021

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.